PharmAbcine Seeks Australian Fast Track For Glioblastoma Candidate
This article was originally published in PharmAsia News
Following an initial clinical study in South Korea, PharmAbcine is progressing with Phase IIa plans in Australia for its anticancer antibody tanibirumab. The South Korean biotech expects to benefit from the country's ‘outstanding’ clinical trial system and is aiming to initially launch the drug in Australia through a fast-track approval system without a Phase III program.
Register for our free email digests: